Carillon Tower Advisers released its third-quarter 2025 investor letter, highlighting the S&P 500 Index’s 13.7% year-to-date returns and the market’s reliance on AI deployment. AbbVie Inc. (NYSE:ABBV) was a key stock mentioned, with a one-month return of -0.46% and shares gaining 32.18% over the last 52 weeks, closing at $225.17 per share on November 11, 2025.

In the investor letter, Carillon Eagle Growth & Income Fund noted AbbVie Inc. (NYSE:ABBV) issued a strong second-quarter financial update, with increased 2025 guidance and a legal settlement providing three additional years of patent protection for a key product. AbbVie Inc. (NYSE:ABBV) reported total net revenues of nearly $15.8 billion in Q3 2025, surpassing expectations by approximately $300 million.

AbbVie Inc. (NYSE:ABBV) is held by 89 hedge fund portfolios, up from 86 in the previous quarter, and has proven itself as a dividend-paying stock with stability. While acknowledging AbbVie’s potential, some believe certain AI stocks offer greater upside potential with less downside risk. For more on DRIP stocks and hedge fund investor letters from Q3 2025, visit the provided links for additional insights.

Read more at Yahoo Finance: AbbVie (ABBV) Surged Following Strong Results and Increased Guidance